* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download When Do Consumer Products Become Medicine?
Survey
Document related concepts
Transcript
White Paper Catalysts driving successful decisions in life sciences. When Do Consumer Products Become Medicine? by Jessica Santos, Ph.D. June 2015 www.kantarhealth.com When Do Consumer Products Become Medicine? As an increasing number of consumer products such as cosmetics and healthy foods claim to have medical benefits, the boundary between fast-moving consumer goods (FMCG) and medicines or medical devices is blurring. Complicating matters further, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the European Commission (EC) offer different opinions on key questions. For example, the FDA classifies the electric toothbrush as a medical device because it is intended to prevent tooth decay.1 However, the EC says it’s not a medical device because it is for hygiene purposes and is a modification of the conventional toothbrush.2 Ambiguity raises tremendous challenges for healthcare Getting the Classification Right Ambiguity such as this raises tremendous challenges for healthcare researchers, who often work with products for which they have yet to fully commit to a classification. Researchers are often faced with a host of critical questions, such as: researchers, who • Which guideline and legislation should we use? often work with • Which association or competent authority should we notify? products for which they have yet to fully commit to a classification. • Is product testing allowed, and if so, how? What’s more, testing food and testing drugs are completely different ballgames. While supermarkets regularly offer food-tasting stalls without consumer screening, the thought of pharmacies providing antibiotics or leukemia drugs for testing is simply absurd. Nonetheless, key considerations for consumer products with medicinal benefits include: • W ill adverse-events reporting procedures change along with the classification? • H ow is the product used to treat “inbetweeners,” e.g., a facial moisturizer that calms eczema? Should participants take a certain degree of risk, as for most FMCGs; or should the sponsor ultimately control and manage risk, as in clinical trials? Manufacturers need to understand the exact classification of their products for research and development, testing, production and marketing. That means understanding that consumer attitudes toward consumer and medical products are completely different in terms of potential risk, usage and consumption. Healthcare researchers must understand the product classification position to properly design a study – from recruitment and execution, to publication within the correct regulatory framework. What Are Medicines and Medical Devices? A medicine, or drug, is a chemical substance or therapeutic agent that has known biological effects on humans or other animals and is used in the prevention, diagnosis, alleviation, treatment or cure of disease.3 Foods are generally excluded from this definition, despite their physiological effects on animal species. A medical device is medical technology used in the diagnosis, prevention, monitoring, treatment or alleviation of disease or disability. Interestingly, a medical device does not achieve its primary effect by pharmacological, immunological or metabolic means.4 Medicines and medical devices are classified in a very detailed way.5 For medicines, the classifications can range from an over-thecounter (OTC) cold remedy that contains mainly Vitamin C to chemotherapy drugs. For medical devices, the range varies greatly as When Do Consumer Products Become Medicine? well, from walking sticks to pacemakers and implants. Because of these broad definitions, once a product claims a medical benefit it may be classified as a medical product. This has led to many debates, with discussions often centered on the medicinal benefits of herbal medicines, food supplements and cosmetics. Additionally, well-publicized U.S. debate continues on whether marijuana is a healing herb or a dangerous drug.6 Regulating Medicinal and Consumer Products To alleviate confusion in the marketplace, regulatory bodies around the world are developing guidelines and updating existing ones to better classify products. To alleviate confusion in the marketplace, regulatory bodies around the world are developing guidelines and updating existing ones to better classify products, but these efforts are in progress and will take time to complete. Nonetheless, enormous variation exists by country, region and how a product is marketed. In the United States, the FDA governs the safety and efficacy of medical products, foods, tobacco and cosmetics, including OTC and prescription drugs. In Europe, the EMA regulates only medicine, while medical devices are CE marked by manufacturers themselves, inspected by EU notified bodies, and audited by each country’s competent authority, such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Food and cosmetics are regulated by food standard agencies7 and European Cosmetic Products Regulation (EU Regulation 1223/2009). Herbal medicine is no longer an unregulated territory, as it is now included in the scope of the FDA and EC. FDA lists supplement products as brand herbal remedies.8 The EC’s Directorate General for Health and Consumer Policy (DG SANCO) provided guidance through the publication of the Herbal Directive 2004/24/EC9 on the registration of traditional herbal medicinal products. With herbal substances classified for use in both medicinal products and food,10 the debate in Europe will continue on whether cannabis is a healing herb or dangerous drug.6,11 A product’s medical benefits or ability to prevent, diagnose, alleviate, treat or cure a disease is key to determining whether a product is a medicinal product or a consumer product. It’s noteworthy that some directives12 only becomes active when a product is commercialized and marketed beyond own usage. For example, when a homemade medicine, medical device or cosmetic is used by someone other than the inventor or inventor’s entity. A Checklist – What Researchers Should Do 1.Know your product – It sounds obvious, but you need to research product labeling, classification and dossiers submitted to competent authorities, as these are often not included in the project brief. If a product is seeking additional labeling (e.g., e-cigarettes may claim to have smoking cessation benefits, hence making them a medical device13,14), recognize that information from the public domain may be outdated or not be sufficient. 2.Know your clients – Manufacturers are interested in exploring the benefits of their products, especially medical ones, which means huge marketing potential. Know the intentions of your clients. Do they seek additional benefits of an existing product? Are they encouraged by recent real-world research? Do they seek regulatory approval on another drug or food classification? Such questions are often raised in the boardroom and may not be communicated explicitly to researchers. 3.Know your market – A product that is classified as a food in one country could well be classified as a medicine or a medical device in another, see aforementioned example of electric toothbrush. Regulatory bodies and competent authorities by country or region have their own approval agenda and procedure. Never enter a new market or test a new group of participants without sufficient consultation to understand how the product is perceived in that market. When Do Consumer Products Become Medicine? 4.Know your customers – Whether the research design is an intensive clinical trial, real-world research or consumer-based opinion research, you need to know and understand customer impressions of your product. For example, Dutch citizens have a more relaxed view on cannabis, while people in some countries can purchase antibiotics OTC. While overlap, gray areas and classification changes of medical and consumer products may seem endless, astute observations in this space can lead to educated research decisions that deliver optimum commercialization results. Information by Drug Class. U.S. Food and Drug Administration website. http://www.fda.gov/Drugs/ DrugSafety/InformationbyDrugClass/default.htm 5 Gilman V. The Majirjuana Debate: Healing Herb or Dangerous Drug? National Geographic News. http://news.nationalgeographic.com/ news/2005/06/0621_050621_marijuana.html 6 Food Standards Agency website. http://www.food. gov.uk/ 7 List of Supplement Products from Brand Herbal Remedies. U.S. Food and Drug Administration website. http://www.accessdata.fda.gov/scripts/ h1n1flu/brand_list.cfm?brand=Herbal%20%20 Remedies&cat=Supplement 8 Directive 2004/24/ED of the European Parliament and of the Coucil of 31 March 2004. Official Journal of the European Union. http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0085: 0090:en:PDF 9 Q&A: Registration of Traditional Herbal Medicinal Products. http://ec.europa.eu/dgs/health_consumer/ docs/traditional_herbal_medicinal_products_en.pdf 10 References Cohen MH. FDA regulates electric toothbrushes as medical devices. Complementary & Alternative Medicine Law Blog. http://www.camlawblog.com/ articles/new-regulation/fda-regulates-electrictoothbrushes-as-medical-devices/ 1 Medical Devices directive. Conformance CE Marking & Product Safety. http://www.conformance. co.uk/adirectives/doku.php?id=medical 2 http://www.drugs.com/dict/drug.html; http://www. merriam-webster.com/; http://www.fda.gov/; http:// www.ema.europa.eu/ 3 http://www.drugs.com/dict/drug.html; http://www. merriam-webster.com/; http://www.fda.gov/; http:// www.ema.europa.eu/; https://www.gov.uk/medicinesmedical-devices-blood/medical-devices-regulationsafety 4 510(k) Substantial Equivalence Determination Decision Summary. http://www.accessdata.fda.gov/ cdrh_docs/reviews/k143599.pdf 11 Active implantable medical devices. European Commission website. http://ec.europa.eu/growth/ single-market/european-standards/harmonisedstandards/implantable-medical-devices/index_ en.htm; http://eur-lex.europa.eu/legal-content/en/ ALL/?uri=CELEX:32007L0047; http://www.fda.gov/ MedicalDevices/DeviceRegulationandGuidance/ default.htm 12 Electronic Cigarettes (e-Cigarettes). U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/ PublicHealthFocus/ucm172906.htm 13 Gornall J. Electronic cigarettes: medical device or consumer product? BMJ. 2012;345:e6417. http:// www.bmj.com/content/345/bmj.e6417 14 When Do Consumer Products Become Medicine? For more information, please visit www.kantarhealth.com. About Kantar Health About the Author Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech and medical device and diagnostic companies. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development knowhow, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership. Jessica Santos, Ph.D. Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Our advisory services, built on a solid foundation of market research and data, span three areas critical to bringing new medicines and pharmaceutical products to market – commercial development, clinical strategies and marketing effectiveness. Kantar Health operates in more than 40 countries and employs more than 600 healthcare industry specialists and practitioners, including a high number of medical doctors, epidemiologists, PhDs, PharmDs and pharmacists, and biologists, biochemists and biophysicists. We work across the product lifecycle, from preclinical development to launch, and are experts at bringing multiple stakeholders together to advance the commercialization of pharmaceutical products. Our team acts as catalysts to successful decision making in the life sciences industry, helping our clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. Kantar Health is part of Kantar, the data investment management division of WPP. If you would like us to act as catalysts for you, contact us at www.kantarhealth.com/contactus. Dr. Jessica Santos is the Global Compliance Director in Kantar Health, the largest custom market research company focused on the life sciences industry. She is primarily responsible for providing oversight and support across the 40+ Kantar Health global offices in the areas of regulation, interaction with clients, suppliers and others within Kantar Health, Kantar and WPP. Dr. Santos is responsible for maintaining, anticipating and coordinating all activities with regard to compliance laws/regulations, industry guidelines, pharamcovigilance and client contracts, defining and driving the execution of Kantar Health’s Quality Strategy – our approach to measuring and improving our quality efforts. Dr. Santos is an experienced statistician, analyst, methodologist and market research scientist. She gained her reputation through her publications and professional committee work in the industry. She is a frequent speaker and contributor in major conferences and has a Ph.D. in Marketing, an MRS fellowship and Chartered Marketer status. Dr. Santos is a member of UK Research Ethics Committee, EphMRA, BHBIA and PMRG Government Affairs Committee, reviewer and co-chair of ISPOR, and MRS Professional Development Advisory Board and Examiner.